千红制药(002550.SZ)：2025年中报净利润为2.58亿元、较去年同期上涨41.17%

Core Insights - Q2 2025 financial results show a slight increase in total revenue and a significant rise in net profit, indicating strong performance [1][3] - The company has achieved continuous growth in key financial metrics over the past two years, reflecting operational efficiency and profitability [3] Financial Performance - Total revenue for the first half of 2025 reached 862 million yuan, an increase of 6.18 million yuan or 0.72% year-on-year [1] - Net profit attributable to shareholders was 258 million yuan, up by 75.26 million yuan or 41.17% compared to the same period last year [1] - Operating cash flow showed a net inflow of 146 million yuan [1] Profitability Metrics - The latest gross profit margin stands at 56.31%, an increase of 1.92 percentage points from the previous quarter and 3.61 percentage points year-on-year, marking three consecutive years of growth [3] - Return on equity (ROE) is reported at 9.83%, up by 2.04 percentage points from the same period last year [3] - Diluted earnings per share increased to 0.21 yuan, reflecting a rise of 0.06 yuan or 41.73% year-on-year [3] Efficiency Ratios - Total asset turnover ratio is 0.30 times [3] - Inventory turnover ratio improved to 0.96 times, an increase of 0.19 times or 25.42% year-on-year [3] Shareholder Structure - The number of shareholders is reported at 72,800, with the top ten shareholders holding 581 million shares, accounting for 45.39% of total equity [3] - The largest shareholder, Wang Yaofang, holds 19.96% of the shares [3]